Search

Your search keyword '"Hernandez M.-T."' showing total 34 results
Start Over Author "Hernandez M.-T." Search Limiters Available in Library Collection
34 results on '"Hernandez M.-T."'

1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

Author

Medina-Herrera, A., Vazquez, I., Cuenca, I., Rosa-Rosa, J. M., Ariceta, B., Jimenez, C., Fernandez-Mercado, M., Larrayoz, M. J., Gutierrez, N. C., Fernandez-Guijarro, M., Gonzalez-Calle, V., Rodriguez-Otero, P., Oriol, A., Rosiñol, L., Alegre, A., Escalante, F., De La Rubia, J., Teruel, A. I., De Arriba, F., Hernandez, M. T., Lopez-Jimenez, J., Ocio, E. M., Puig, N., Paiva, B., Lahuerta, J. J., Bladé, J., San Miguel, J. F., Mateos, M. V., Martinez-Lopez, J., Calasanz, M. J., and Garcia-Sanz, R.

Published
2024
Full Text
View/download PDF

2. Mass of the compact object in the Be/gamma-ray binaries LSI+61303 and MWC 148

Author

Zamanov, R. K., Marti, J., and Garcia-Hernandez, M. T.

Subjects
Astrophysics - High Energy Astrophysical Phenomena, Astrophysics - Solar and Stellar Astrophysics
Abstract

We estimate the mass of the compact object in the gamma-ray binaries LSI+61303 and MWC 148, using the latest data for the inclination, orbital motion and assuming that the orbital plane coincides with the equatorial plane of the Be star. For LSI+61303 we find the mass of the compact object to be most likely in the range 1.3 M_sun < M_2 < 2.0 M_sun, which means that it is probably a neutron star. For MWC 148, we find the mass of the compact object in a higher range, 2.1 M_sum < M_2 < 7.3 M_sun, which increases the chances for this system to host a black hole companion., Comment: 4 pages, submitted

Published
2017

4. Differentiation stage of myeloma plasma cells: biological and clinical significance

Author

Paiva, B, Puig, N, Cedena, M T, de Jong, B G, Ruiz, Y, Rapado, I, Martinez-Lopez, J, Cordon, L, Alignani, D, Delgado, J A, van Zelm, M C, Van Dongen, J J M, Pascual, M, Agirre, X, Prosper, F, Martín-Subero, J I, Vidriales, M-B, Gutierrez, N C, Hernandez, M T, Oriol, A, Echeveste, M A, Gonzalez, Y, Johnson, S K, Epstein, J, Barlogie, B, Morgan, G J, Orfao, A, Blade, J, Mateos, M V, Lahuerta, J J, and San-Miguel, J F

Published
2017
Full Text
View/download PDF

5. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Author

Perez C., Botta C., Zabaleta A., Puig N., Cedena M. -T., Goicoechea I., Alameda D., Jose-Eneriz E. S., Merino J., Rodriguez-Otero P., Maia C., Alignani D., Maiso P., Manrique I., Lara-Astiaso D., Vilas-Zornoza A., Sarvide S., Riillo C., Rossi M., Rosinol L., Oriol A., Blanchard M. -J., Rios R., Sureda A., Martin J., Martinez R., Bargay J., de la Rubia J., Hernandez M. -T., Martinez-Lopez J., Orfao A., Agirre X., Prosper F., Mateos M. -V., Lahuerta J. -J., Blade J., San-Miguel J. F., Paiva B., Espinosa M. C., Zamudio J. L. G., Herranz E. R., Tamayo R. R., Sanchez J. M., Bernal L. P., Rodriguez A. P. G., Garcia M. E. G., Mayol A. S., Lleonart J. B., Suarez A., Garcia M. T. H., Gaisan C. M., Ruiz B. H., Montero F. C., de Miguel Llorente D., Ramos F. S., Garcia A. I., Manteca M. M., Martin J. M. H., Barrigon F. E., Frade J. G., de Coca A. G., Franco C. A., Gomez J. L., Perez E. C., Creixenti J. B., Balari A. M. S., Montes Y. G., Teigell L. E., Guinon A. G., Monreal E. A., Campos J. A. S., Tutusaus J. M. M., Rocafiguera A. O., Gorrochategui M. G., Mesa M. G., Silva C. C., Perez M. S. G., Loureiro A. D., Sanchez J. A. M., Irazu M. J. N., Parraga F. J. P., Palacios J. J. L., Barahona P. B., Rodriguez C. E., Rivas J. A. H., de Oteyza J. P., del Barrio R. I., de la Guia A. L., Amor A. A., Pareja E. P., Castello I. K., Rodriguez M. J. B., Martinez R. M., Grau R. R., Mesa E. G., Sainz E. R., de Arriba F., Jimenez J. M. M., Romera M., Cardoso F. P., Perez J. M. A., Pomposo M. P., Persona E. P., Casasus A. I. T., Garcia P. R., Ramos I. J., Lor M. B. V., Garcia P. L. F., Chamorro C. M., Perez C., Botta C., Zabaleta A., Puig N., Cedena M.-T., Goicoechea I., Alameda D., Jose-Eneriz E.S., Merino J., Rodriguez-Otero P., Maia C., Alignani D., Maiso P., Manrique I., Lara-Astiaso D., Vilas-Zornoza A., Sarvide S., Riillo C., Rossi M., Rosinol L., Oriol A., Blanchard M.-J., Rios R., Sureda A., Martin J., Martinez R., Bargay J., de la Rubia J., Hernandez M.-T., Martinez-Lopez J., Orfao A., Agirre X., Prosper F., Mateos M.-V., Lahuerta J.-J., Blade J., San-Miguel J.F., Paiva B., Espinosa M.C., Zamudio J.L.G., Herranz E.R., Tamayo R.R., Sanchez J.M., Bernal L.P., Rodriguez A.P.G., Garcia M.E.G., Mayol A.S., Lleonart J.B., Suarez A., Garcia M.T.H., Gaisan C.M., Ruiz B.H., Montero F.C., de Miguel Llorente D., Ramos F.S., Garcia A.I., Manteca M.M., Martin J.M.H., Barrigon F.E., Frade J.G., de Coca A.G., Franco C.A., Gomez J.L., Perez E.C., Creixenti J.B., Balari A.M.S., Montes Y.G., Teigell L.E., Guinon A.G., Monreal E.A., Campos J.A.S., Tutusaus J.M.M., Rocafiguera A.O., Gorrochategui M.G., Mesa M.G., Silva C.C., Perez M.S.G., Loureiro A.D., Sanchez J.A.M., Irazu M.J.N., Parraga F.J.P., Palacios J.J.L., Barahona P.B., Rodriguez C.E., Rivas J.A.H., de Oteyza J.P., del Barrio R.I., de la Guia A.L., Amor A.A., Pareja E.P., Castello I.K., Rodriguez M.J.B., Martinez R.M., Grau R.R., Mesa E.G., Sainz E.R., de Arriba F., Jimenez J.M.M., Romera M., Cardoso F.P., Perez J.M.A., Pomposo M.P., Persona E.P., Casasus A.I.T., Garcia P.R., Ramos I.J., Lor M.B.V., Garcia P.L.F., and Chamorro C.M.

Subjects
Male, Transcription, Genetic, Neutrophils, T-Lymphocytes, Immunology, CD33, Biology, CD16, Biochemistry, Follow-Up Studie, Flow cytometry, Antigens, CD, medicine, Humans, Cytotoxic T cell, Lymphocyte Count, Tumor microenvironment, medicine.diagnostic_test, Myeloid-Derived Suppressor Cells, Cell Biology, Hematology, Middle Aged, Cell sorting, Neoplasm Proteins, medicine.anatomical_structure, T-Lymphocyte, Cancer research, Myeloid-derived Suppressor Cell, Female, Bone marrow, Multiple Myeloma, Human, Follow-Up Studies
Abstract

Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phenotypic profile of G-MDSCs based on their prognostic significance in MM, immunosuppressive potential, and molecular program. The preestablished phenotype of G-MDSCs was evaluated in bone marrow samples from controls and MM patients using multidimensional flow cytometry; surprisingly, we found that CD11b+CD14−CD15+CD33+HLADR− cells overlapped with common eosinophils and neutrophils, which were not expanded in MM patients. Therefore, we relied on automated clustering to unbiasedly identify all granulocytic subsets in the tumor microenvironment: basophils, eosinophils, and immature, intermediate, and mature neutrophils. In a series of 267 newly diagnosed MM patients (GEM2012MENOS65 trial), only the frequency of mature neutrophils at diagnosis was significantly associated with patient outcome, and a high mature neutrophil/T-cell ratio resulted in inferior progression-free survival (P < .001). Upon fluorescence-activated cell sorting of each neutrophil subset, T-cell proliferation decreased in the presence of mature neutrophils (0.5-fold; P = .016), and the cytotoxic potential of T cells engaged by a BCMA×CD3-bispecific antibody increased notably with the depletion of mature neutrophils (fourfold; P = .0007). Most interestingly, RNA sequencing of the 3 subsets revealed that G-MDSC–related genes were specifically upregulated in mature neutrophils from MM patients vs controls because of differential chromatin accessibility. Taken together, our results establish a correlation between the clinical significance, immunosuppressive potential, and transcriptional network of well-defined neutrophil subsets, providing for the first time a set of optimal markers (CD11b/CD13/CD16) for accurate monitoring of G-MDSCs in MM.

Published
2020

7. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Author

Medina, Alejandro, Puig, N., Flores-Montero, Juan, Jimenez, C., Sarasquete, M. E., García-Álvarez, M., Prieto-Conde, I., Chillon, C., Alcoceba, Miguel, Gutierrez, N. C., Oriol, Albert, Rosinol, L., Bladé Creixenti, Juan, Gironella, Mercedes, Hernandez, M. T., Gonzalez-Calle, V., Cedena, María Teresa, Paiva, Bruno, San-Miguel, J., Lahuerta, J. J., Mateos, M. V., Martínez-López, Joaquín, Orfao, Alberto, Gonzalez, M, García-Sanz, Ramón, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Medina A, Puig N, Jimenez C, Sarasquete ME, Garcia-Alvarez M] Departamento de Hematología, Hospital Universitario de Salamanca (HUSA/ IBSAL), CIBERONC, CIC-IBMCC (USAL-CSIC), Salamanca, Spain. [Flores-Montero J] Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. [Gironella M] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Nucleòtids - Anàlisi, Neoplasm, Residual, Myeloma, lcsh:RC254-282, Disease-Free Survival, Article, DNA sequencing, EuroFlow, Internal medicine, medicine, neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES], Humans, In patient, Survival rate, Multiple myeloma, Proportional hazards model, business.industry, Mieloma múltiple, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES], High-Throughput Nucleotide Sequencing, Hematology, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Flow Cytometry, medicine.disease, Minimal residual disease, técnicas de investigación::técnicas genéticas::análisis de secuencias [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Survival Rate, Transplantation, Investigative Techniques::Genetic Techniques::Sequence Analysis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Risk factors, Female, Multiple Myeloma, business, Follow-Up Studies
Abstract

© The Author(s) 2020., Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with nextgeneration flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R2 = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09–0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06–0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.

Published
2020

9. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

Author

Paiva, B, Pérez-Andrés, M, Vídriales, M-B, Almeida, J, de las Heras, N, Mateos, M-V, López-Corral, L, Gutierrez, N C, Blanco, J, Oriol, A, Hernandez, M T, de Arriba, F, de Coca, A G, Terol, M-J, de la Rubia, J, Gonzalez, Y, Martín, A, Sureda, A, Schmidt-Hieber, M, Schmitz, A, Johnsen, H E, Lahuerta, J-J, Bladé, J, San-Miguel, J F, and Orfao, A

Published
2011
Full Text
View/download PDF

10. PS1351 CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL

Author

Ubieto, A. Jiménez, primary, Martinez-Lopez, J., additional, Paiva, B., additional, Rosiñol, L., additional, Gonzalez-Medina, J., additional, Puig, N., additional, Cedena, T., additional, Calasanz, M.J., additional, Ramos, M.L., additional, Alonso, R., additional, Oriol, A., additional, Blanchard, M.J., additional, Ríos, R., additional, Martin, J.M., additional, Martinez, R., additional, Sarra, J., additional, Hernandez, M.-T., additional, de la Rubia, J., additional, Krnisk, I., additional, Moraleda, J.M., additional, Palomera, L., additional, Bargay, J., additional, Mateos, M.V., additional, Blade, J., additional, Miguel, J. San, additional, and Lahuerta, J.J., additional

Published
2019
Full Text
View/download PDF

13. Airborne observations of regional variation in fluorescent aerosol across the United States

Author

Massachusetts Institute of Technology. Department of Civil and Environmental Engineering, Heald, Colette L., Perring, A. E., Schwarz, J. P., Baumgardner, D., Hernandez, M. T., Spracklen, D. V., Gao, R. S., Kok, G., McMeeking, G. R., McQuaid, J. B., Fahey, D. W., Massachusetts Institute of Technology. Department of Civil and Environmental Engineering, Heald, Colette L., Perring, A. E., Schwarz, J. P., Baumgardner, D., Hernandez, M. T., Spracklen, D. V., Gao, R. S., Kok, G., McMeeking, G. R., McQuaid, J. B., and Fahey, D. W.

Abstract

Airborne observations of fluorescent aerosol were made aboard an airship during CloudLab, a series of flights that took place in September and October of 2013 and covered a wideband of longitude across the continental U.S. between Florida and California and between 28 and 37 N latitudes. Sampling occurred from near the surface to 1000 m above the ground. A Wideband Integrated Bioaerosol Sensor (WIBS-4) measured average concentrations of supermicron fluorescent particles aloft (1 µm to 10 µm), revealing number concentrations ranging from 2.1 ± 0.8 to 8.7 ± 2.2 × 10[superscript 4] particles m[superscript −3] and representing up to 24% of total supermicron particle number. We observed distinct variations in size distributions and fluorescent characteristics in different regions, and attribute these to geographically diverse bioaerosol. Fluorescent aerosol detected in the east is largely consistent with mold spores observed in a laboratory setting, while a shift to larger sizes associated with different fluorescent patterns is observed in the west. Fluorescent bioaerosol loadings in the desert west were as high as those near the Gulf of Mexico, suggesting that bioaerosol is a substantial component of supermicron aerosol both in humid and arid environments. The observations are compared to model fungal and bacterial loading predictions, and good agreement in both particle size and concentrations is observed in the east. In the west, the model underestimated observed concentrations by a factor between 2 and 4 and the prescribed particle sizes are smaller than the observed fluorescent aerosol. A classification scheme for use with WIBS data is also presented., National Science Foundation (U.S.) (AGS-1238109)

Published
2016

19. Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials

Author

Arana, P, Paiva, B, Cedena, M-T, Puig, N, Cordon, L, Vidriales, M-B, Gutierrez, N C, Chiodi, F, Burgos, L, Anglada, L-L, Martinez-Lopez, J, Hernandez, M-T, Teruel, A-I, Gironella, M, Echeveste, M-A, Rosiñol, L, Martinez, R, Oriol, A, De la Rubia, J, Orfao, A, Blade, J, Lahuerta, J-J, Mateos, M-V, and San Miguel, J-F

Abstract

Persistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great heterogeneity with both early and very late relapses. Among different MRD techniques, flow cytometry provides additional information about antigen expression on tumor cells, which could potentially contribute to stratify MRD-positive patients. We investigated the prognostic value of those antigens required to monitor MRD in 1265 newly diagnosed patients enrolled in the GEM2000, GEM2005MENOS65, GEM2005MAS65 and GEM2010MAS65 protocols. Overall, CD19pos, CD27neg, CD38lo, CD45pos, CD81pos, CD117negand CD138loexpression predicted inferior outcomes. Through principal component analysis, we found that simultaneous CD38lowCD81posCD117negexpression emerged as the most powerful combination with independent prognostic value for progression-free survival (HR:1.69; P=0.002). This unique phenotypic profile retained prognostic value among MRD-positive patients. We then used next-generation flow to determine antigen stability throughout the course of the disease, and found that the expression of antigens required to monitor MRD is mostly stable from diagnosis to MRD stages, except for CD81 whose expression progressively increased from baseline to chemoresistant tumor cells (14 vs 28%). Altogether, we showed that the phenotypic profile of tumor cells provides additional prognostic information, and could be used to further predict risk of relapse among MRD-positive patients.

Published
2018
Full Text
View/download PDF

22. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

Author

Mateos, M.-V., primary, Hernandez, J. M., additional, Hernandez, M. T., additional, Gutierrez, N. C., additional, Palomera, L., additional, Fuertes, M., additional, Garcia-Sanchez, P., additional, Lahuerta, J. J., additional, de la Rubia, J., additional, Terol, M.-J., additional, Sureda, A., additional, Bargay, J., additional, Ribas, P., additional, Alegre, A., additional, de Arriba, F., additional, Oriol, A., additional, Carrera, D., additional, Garcia-Larana, J., additional, Garcia-Sanz, R., additional, Blade, J., additional, Prosper, F., additional, Mateo, G., additional, Esseltine, D.-L., additional, van de Velde, H., additional, and San Miguel, J. F., additional

Published
2008
Full Text
View/download PDF

27. SERUM-FREE LIGHT-CHAINS (SFLC) INSTEAD OF URINE PROTEIN ELECTROPHORESIS (UPEP) FOR MONITORING LIGHT-CHAIN MULTIPLE MYELOMA (LCMM)

Author

Anglada Fernandez, L. Lopez, Cueto-Felqueroso, C., Mateos, M. V., Rosinol, L., Oriol, A., Teruel, A. I., Palomera, L., Arriba, F., Bargay, J. J., Hernandez, J. M., Gonzalez, Y., Maria Jesus, B., Valeri, A., Granell, M., Garcia Sanz, R., Lopez La Guia, A., Besalduch, J., Martinez, R. B., Hernandez, M. T., Puerta, P., Blade, J., San Miguel, J., Juan José Lahuerta, and Martinez-Lopez, J.

28. CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. UPDATING DATA BASED ON PHASE 3 STUDY PETHEMA/GEM2012MINUS65

Author

Jimenez Ubieto, A., Martinez Lopez, J., Bruno, P., Rosinol, L., Gonzalez Medina, J., Puig, N., Cedena, M. T., Calasanz, M. J., Ramos, M. L., Alonso, R., Oriol, A., Blanchard, M. J., Rios, R., Martin, J., Martinez, R., Sarra, J., Hernandez, M. T., La Rubia, J., Krnisk, I., Moraleda, J. M., Palomera, L., Mateos, M., Blade, J., San Miguel, J., and Juan José Lahuerta

29. CRITICAL REVIEW OF THE DOUBLE NEGATIVITY IN THE SERUM AND URINE IMMUNOFIXATION (IF) TO ESTABLISH THE CATEGORY OF COMPLETE REMISSION IN MULTIPLE MYELOMA (MM)

Author

Lopez Anglada, L., Jimenez Ubieto, A., Mateos, M., Rosinol, L., Oriol, A., Rios, R., Jarque, I., Palomera, L., Arriba, F., Bargay, J., Garcia Sanz, R., Besalduch, J., Mendez, J. A., Gonzalez, Y., Martinez, R. B., Hernandez, M. T., Valeri, A., Escalante, F., Blanchard, M. J., J, Blade, San Miguel, J., Joaquin Martinez-Lopez, and Lahuerta, J. J.

30. ANALYSIS OF RESIDUAL DISEASE IN PERIPHERAL BLOOD BY MEANS OF MASS SPECTROMETRY IN PATIENTS WITH MULTIPLE MYELOMA OF THE GEM 2012 MINUS65. COMPARISON WITH THE IMWG STANDARD RESPONSE AND RESIDUAL DISEASE CRITERIA

Author

Puig, N., Contreras, T., Paiva, B., Cedena, M. T., Rosinol, L., Garcia-Sanz, R., Martinez-Lopez, J., Oriol, A., Blanchard, M. J., Rios, R., Martin, J., Sureda, A., Hernandez, M. T., La Rubia, J., Krsnik, I., Moraleda, J. M., Palomera, L., Inigo, M., Agullo, C., Bargay, J., Blade, J., San Miguel, J. F., Juan José Lahuerta, and Mateos, M.

32. Going North: Mexican migrants and their vulnerability to HIV.

Author

Magis-Rodríguez C, Lemp G, Hernandez MT, Sanchez MA, Estrada F, and Bravo-García E

Subjects
Adolescent, Adult, Female, HIV Infections prevention & control, HIV Infections transmission, Humans, Incidence, Male, Mexican Americans, Mexico, Middle Aged, Risk Factors, Sexual Behavior, Substance-Related Disorders, Transients and Migrants, United States, Young Adult, HIV Infections epidemiology
Abstract

Background: Mexican migrants are at higher risk for HIV than Mexicans who do not migrate to the United States. Migration to the United States was the driving factor of the early Mexican HIV epidemic, and it is likely that it continues to strongly influence incidence. An overview of migration of Mexicans to the United States identifies many pervasive environmental and structural factors as well as risk behaviors that render migrants vulnerable to HIV infection. However, published studies sampling Mexicans while in the United States suggest a relatively low prevalence of HIV among the general migrant population. To better understand this apparent paradox, we sought to identify any demographic variables among Mexicans while in Mexico that may indicate that migrants have or acquire resources that have a protective effect from their vulnerability due to migration., Methods: A California-Mexico binational collaboration project, with a respondent-driven sample with population-based quotas, was conducted in five Mexican states from December 2004 to January 2005, in areas with a high index of migration to the United States. We compared demographic and behavior variables of Mexicans with a history of migration to the United States in the past 12 months to nonmigrant Mexicans living in the same community., Results: A total of 1539 migrants and 1236 nonmigrants were recruited from five Mexican states. Migrants (men and women) reported more HIV risk behavior than nonmigrants in the past 12 months. Migrants reported more sexual partners and noninjected drug use. Migrants reported higher condom use during vaginal sex and were more likely to have taken an HIV test., Conclusion: Though migrants reported higher HIV-related risk behaviors, they also reported higher condom use. Migrants were more likely to have accessed an HIV test indicating an opportunity for a prevention intervention. More binational collaborations are needed to research the different levels of vulnerability among Mexican migrants and actual acquisition of HIV infection. In addition, more research is needed to identify protective factors for HIV prevention interventions among Mexican migrant communities in Mexico and in the United States.

Published
2009
Full Text
View/download PDF

33. Knock-knock: a population-based survey of risk behavior, health care access, and Chlamydia trachomatis infection among low-income women in the San Francisco Bay area.

Author

Klausner JD, McFarland W, Bolan G, Hernandez MT, Molitor F, Lemp GF, Cahoon-Young B, Morrow S, and Ruiz J

Subjects
Adolescent, Adult, Black or African American, California epidemiology, Cohort Studies, Female, Government Programs statistics & numerical data, Hispanic or Latino, Humans, Insurance, Health, Prevalence, Risk Factors, Chlamydia Infections epidemiology, Chlamydia trachomatis, Genital Diseases, Female epidemiology, Population Surveillance, Poverty
Abstract

To estimate the prevalence of urogenital chlamydial infection among young, low-income women in northern California and to describe correlates of infection, a population-based door-to-door household cluster survey was conducted from 1996 through 1998. The participants included 1439 women 18-29 years of age, with a mean age of 24 years, most of whom were African American (43%) or Latina (23%) and had a median income of $500-$999 per month. Most (94%) had received health care in the past year, and approximately 50% was covered by state insurance programs. Although more than half (62%) had had a recent pelvic examination, only 42% had recently used a condom with a new partner. The prevalence of urogenital chlamydial infection was 3.2% (95% confidence interval, 2.2%-4.2%). Women with chlamydia were more likely to be younger (18-21 years of age) and nonwhite and to have lower socioeconomic status. These data demonstrated an approximately 2-3-fold greater burden of infection than routine surveillance data have suggested.

Published
2001
Full Text
View/download PDF

34. Fate and toxicity of aircraft deicing fluid additives through anaerobic digestion.

Author

Gruden CL, Dow SM, and Hernandez MT

Subjects
Aircraft, Biomass, Fatty Acids, Population Dynamics, Toxicity Tests, Triazoles chemistry, Volatilization, Waste Disposal, Fluid, Archaea physiology, Bacteria, Anaerobic physiology, Triazoles toxicity
Abstract

Benzotriazole derivatives are widely used corrosion inhibitors and their fate during wastewater treatment processes is unknown. The purpose of this research was to study the toxic effects and fate of the two commercially significant benzotriazole isomers used in aircraft deicing fluids (4-, and 5-, methylbenzotriazole [MeBT]) during anaerobic digestion. Experiments were executed in microcosms using mesophilic anaerobic biomass co-digesting wastewater sludge and propylene glycol. Sorption of MeBT to digesting solids could be approximated with a Freundlich model, and no anaerobic breakdown of either MeBT isomer was detected. Digesters fed more than 300 mg/L MeBT responded with a significant decrease in methanogenic microbial activity and volatile solids production and a concomitant increase in accumulation of volatile fatty acids. Direct microscopic measurements using fluorescent phylogenetic probes applied to digesting biomass revealed that members of both Archaea and Bacteria domains were sensitive to MeBT. Granular activated carbon (GAC) (volatile solids: GAC = 10%) reduced the apparent toxic effects of MeBT; GAC addition nearly restored the baseline activity of digesters fed MeBT (500 to 1000 mg/L).

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results